Cowley A J, Fullwood L, Stainer K, Hampton J R
Department of Medicine, University Hospital, Nottingham, England.
Eur Heart J. 1991 Jan;12(1):50-4. doi: 10.1093/oxfordjournals.eurheartj.a059824.
The exercise capability of 12 patients with heart failure was investigated by a variety of different methods before and after treatment with the vasodilator flosequinan. Two treadmill protocols were used, a modified Bruce with incremental workloads and a fixed workload protocol. On placebo, mean exercise time was greater with the Bruce protocol, 526 (64) s, than with the fixed protocol, 359 (59) s, P less than 0.005. Flosequinan increased exercise time more with the fixed protocol, so after 5 weeks' treatment exercise time was the same with both protocols; 680 (64) s with the Bruce and 673 (147) s with the fixed protocol. When the results are expressed as work, the patients achieved less with the Bruce protocol, 7.8 (1.9) kJ, than with the fixed protocol 12.5 (1.5) kJ on placebo, P less than 0.01. After flosequinan, the respective values were 14.5 (2.8) and 25.3 (5.1) kJ. Flosequinan improved corridor walk test times but there was no relationship between this and either treadmill test. Pedometer scores of customary activity were unchanged by flosequinan and were not correlated with any other exercise test. Different methods of assessing exercise capability provide different measures of patients' incapacity.
采用多种不同方法对12例心力衰竭患者在使用血管扩张剂氟司喹南治疗前后的运动能力进行了研究。使用了两种跑步机方案，一种是工作量递增的改良布鲁斯方案，另一种是固定工作量方案。服用安慰剂时，布鲁斯方案的平均运动时间更长，为526（64）秒，而固定方案为359（59）秒，P<0.005。氟司喹南在固定方案中使运动时间增加得更多，因此在治疗5周后，两种方案的运动时间相同；布鲁斯方案为680（64）秒，固定方案为673（147）秒。当结果以功表示时，服用安慰剂时，患者在布鲁斯方案中完成的功较少，为7.8（1.9）千焦，而在固定方案中为12.5（1.5）千焦，P<0.01。使用氟司喹南后，相应的值分别为14.5（2.8）和25.3（5.1）千焦。氟司喹南改善了走廊步行试验时间，但这与两种跑步机试验均无关联。氟司喹南对日常活动计步器评分无影响，且与任何其他运动试验均无相关性。不同的运动能力评估方法提供了对患者运动能力丧失的不同衡量标准。
